# Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention

Study · id `cardio:ct-nct04899479` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04899479](<https://clinicaltrials.gov/study/NCT04899479>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04899479

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04899479. Randomized; no masking; primary purpose treatment. Start 2021-07-05 (actual); primary completion 2025-08-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04899479, source copy `cardio:ctgov-nct04899479-2025-06-26`, retrieved 2026-10-26)
- Started: 2021-07-05 (actual) (ClinicalTrials.gov record NCT04899479, source copy `cardio:ctgov-nct04899479-2025-06-26`, retrieved 2026-10-26)
- Primary completion: 2025-08-31 (anticipated) (ClinicalTrials.gov record NCT04899479, source copy `cardio:ctgov-nct04899479-2025-06-26`, retrieved 2026-10-26)
- Completion: 2025-12-30 (anticipated) (ClinicalTrials.gov record NCT04899479, source copy `cardio:ctgov-nct04899479-2025-06-26`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04899479, source copy `cardio:ctgov-nct04899479-2025-06-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04899479-2025-06-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention
- Acronym: PRESTIGE-AMI
- Condition: Acute Myocardial Infarction
- Condition: Heart Failure
- Intervention (Drug): SGLT2 inhibitor
- Intervention (Other): Control
- Lead sponsor: Samsung Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record once doses, forms and salt words are removed: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Samsung Medical Center (`cardio:org-samsung-medical-center`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: SGLT2 Inhibitor on Infarct Size and LV Remodeling by CMR in Patients With AMI (`cardio:pubmed-42508844`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c9ca293fd41c889138941c38ab09f5a2c4bdb038c897a8da06e733151ace675f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
